The genetic basis of severe combined immunodeficiency and its variants

Diana Tasher¹,²
Ilan Dalal¹,²
¹The Pediatric Infectious and Immunology Unit, E Wolfson Medical Center, Holon, Israel; ²The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract: Severe combined immunodeficiency (SCID) syndromes are characterized by a block in T lymphocyte differentiation that is variably associated with abnormal development of other lymphocyte lineages (B and/or natural killer [NK] cells), leading to death early in life unless treated urgently by hematopoietic stem cell transplant. SCID comprises genotypically and phenotypically heterogeneous conditions, of which the genetic basis for approximately 85% of the underlying immunologic defects have been recently elucidated. A major obstacle in deciphering the pathogenesis of SCID syndromes is that different mutations in a single gene may give rise to distinct clinical conditions and that a similar clinical phenotype can result from mutations in different genes. Mutation analysis is now an important component of the complete evaluation of a patient with SCID since it has a dramatic impact on many aspects of this potentially life-threatening disease such as genetic counseling, prenatal diagnosis, modalities of treatment, and, eventually, prognosis. Dr Robert Good, one of the founders of modern immunology, described the SCID syndrome as “experiments of nature.” By understanding the cellular and genetic basis of these immunodeficiency diseases and, eventually, normal immunity, we optimize the “bedside to research laboratory and back again” approach to medicine.

Keywords: severe combined immune deficiency, molecular defects, lymphocytes

Human severe combined immunodeficiency (SCID) comprises a group of genotypically and phenotypically heterogeneous diseases. The clinical presentation usually includes severe, recurrent, and potentially lethal infections early in infancy such as chronic diarrhea, failure to thrive, lymphopenia (particularly of T lymphocytes) with profound abnormalities of cell-mediated immunity, and antibody deficiency. Skin rashes might reflect graft-versus-host disease caused by maternal T-cell engraftment in infants with SCID or tissue damage caused by the infiltration of activated, autologous T lymphocytes, as is typically seen in Omenn syndrome (OS). In addition, some forms of SCID are associated with distinctive features in other systems.

SCID is a syndrome caused by mutations in different genes whose products are crucial for the development and function of both T and B cells. In some cases, the molecular defect prevents only T-cell function, while B cells are normal. Natural killer (NK) cells, a lymphocyte subset exhibiting cytotoxic activities, develop via a pathway that is distinct from B and T cells. NK cells are present in approximately 50% of patients with SCID, and provide a degree of protection against bacterial and viral infections in these patients, and, ultimately, a better prognosis.
SCID immunophenotypes can be classified according to the presence (T–B+ SCID) or absence (T–B– SCID) of B cells in the peripheral blood. Both main groups of SCID include forms with or without NK lymphocytes.

SCID can also be categorized based on the cellular function of the protein that is encoded by the defective gene. The five functional categories include proteins involved in cytokine signaling, antigen presentation, V(D)J recombination, T-cell receptor (TCR) signaling, and basic cellular functions.

SCID syndromes have a prevalence of approximately 1:50,000 live births and are more common in male subjects, reflecting the overrepresentation of X-linked SCID (XL-SCID), the most common worldwide form (1–3% of SCID in human subjects).1–3

However, in cultures in which consanguineous marriage is common, the incidence of autosomal recessive (AR) SCID is higher than has been previously reported.4,5

Gene defects are present in approximately 85% of SCID cases.1 Thus, mutation analysis in the characterization of SCID is now an important component of the complete evaluation of a patient, particularly as affected genes associated with this group of diseases continue to increase. In addition, it has a dramatic impact on many aspects of this potentially life-threatening disease such as genetic counseling, prenatal diagnosis, modalities of treatment, and, eventually, prognosis.

**Normal T-cell development and activation**

Before discussing the different types of SCID phenotypes, one should describe the normal steps involved in T-cell development, maturation, differentiation, and activation. Each step in the normal process that generates normal, functional T cells is genetically controlled by many structural and regulatory genes, and, therefore, the potential for genetic defects resulting in an abnormal number or function of T cells – and subsequently, SCID phenotype – is great.

Pluripotential hematopoietic stem cells develop into lymphoid stem cells, which differentiate into T, B, or NK cells depending on the organs or tissues to which these stem cells migrate. T-cell progenitors occur in the embryonic thymus as early as 8 weeks of gestation and, by the age of 10 weeks, 25% of thymocytes bear the mature, specific T-cell receptor (TCR). TCRs consist of two chains (α and β) that are coexpressed on the cell surface with CD3 – a multichain signaling complex of five polypeptides: γ, δ, ε, ζ, and η. Together, the TCR and the CD3 molecule form the TCR complex. This complex also includes tyrosine phosphatase CD45, which is found on all hematopoietic cells and is essential for the normal maturation of T cells. Early development of TCR in the thymus requires the expression of specific markers such as CD1, CD2, and interleukin-2 receptor (IL-2R) molecules, which serve critical receptor-ligand functions during the early stages of ontogeny. The next step involves the lymphoid-specific recombinase activating genes (RAG)1 and RAG2, which are responsible for the V(D)J rearrangement process, and are critical for the normal development of TCRs. As immature cortical thymocytes begin to express TCRs, they move through the processes of positive and negative selection. Mature T cells that survive positive selection either express CD4 and are restricted to interacting only with self class II molecules or express CD8 and are restricted to interacting with self class I human histocompatibility leukocyte antigens (HLAs). The purpose of negative selection is to remove autoreactive T cells and, subsequently, by the end of the process, 97% of all cortical thymocytes die. During negative selection, mature single positive T cells emigrate from the thymus to secondary lymphoid organs such as the spleen, lymph nodes, tonsils, and appendix at 12 weeks of embryonic life. Immune cell interaction is crucial for the adequate response and activation of T cells, since TCRs can only recognize processed antigenic peptides, presented to it by antigen-presenting cells (APCs) such as B cells, macrophages, and dendritic cells, in the context of class I or II HLA molecules. Normal activation of CD4 T cells by B cells requires a transient expression of CD40 ligand molecules on the surface of CD40 T cells, which bind to CD40 molecules on B cells. The TCR then interacts with the peptide-bearing HLA molecule and, through the multichain, CD3 signaling complex, sends a signal to produce cytokines, ultimately resulting in T-cell activation and proliferation. The most important cytokine involved in the activation and proliferation of T cells is IL-2, which binds to its high affinity, multi-chain (α, β, γ) receptor; namely, IL-2R.

Activation of the TCR complex results in the following activation events: (1) Production of lipid mediators such as inositol trisphosphate and diacylglycerol and activation of protein kinase C. (2) Phosphorylation and activation of tyrosine kinases such as Lck and ZAP-70. (3) Elevation of intracellular calcium levels. All these activation events convey messages to the cell nucleus resulting in the normal functioning of T cells.5,7

Although it is more appropriate to refer to SCID syndromes according to the specific molecular defect (once it has been identified), phenotypic classification is still viewed as a simpler, more useful, and more intuitive approach. Thus, we decided to take this approach in order to classify the different types of SCID (Table 1). However, some forms...
Table 1  Classification of SCID syndromes based on immunophenotype

<table>
<thead>
<tr>
<th>Inheritance</th>
<th>Phenotype</th>
<th>Gene/locus</th>
<th>Specific manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-B-NK-</td>
<td>AR</td>
<td>102700</td>
<td>608958</td>
</tr>
<tr>
<td>Adenosine deaminase (ADA) deficiency</td>
<td>AR</td>
<td>102700</td>
<td>608958</td>
</tr>
<tr>
<td>Reticular dysgenesis</td>
<td>AR</td>
<td>267500</td>
<td>103020</td>
</tr>
<tr>
<td>T-B-NK+</td>
<td>RAG1/2 deficiency</td>
<td>AR</td>
<td>601457</td>
</tr>
<tr>
<td>DCLRE1C (Artemis) deficiency</td>
<td>AR</td>
<td>602450</td>
<td>605988</td>
</tr>
<tr>
<td>DNA-PKcs deficiency</td>
<td>AR</td>
<td>600802</td>
<td>605988</td>
</tr>
<tr>
<td>T-B-NK+</td>
<td>Common gamma chain (γc) deficiency</td>
<td>XL</td>
<td>300400</td>
</tr>
<tr>
<td>JAK3 deficiency</td>
<td>AR</td>
<td>602450</td>
<td>605988</td>
</tr>
<tr>
<td>T-B-NK+</td>
<td>IL7Rα deficiency</td>
<td>AR</td>
<td>600802</td>
</tr>
<tr>
<td>Coronin-1 A deficiency</td>
<td>AR</td>
<td>605000</td>
<td>146661</td>
</tr>
<tr>
<td>CD45 deficiency</td>
<td>AR</td>
<td>205200</td>
<td>151460</td>
</tr>
<tr>
<td>CD3δ/ CD3ε/CD3ζ deficiency</td>
<td>AR</td>
<td>608971</td>
<td>186790, 186830</td>
</tr>
</tbody>
</table>

Abbreviations: SCID, severe combined immune deficiencies; XL, X-linked inheritance; AR, autosomal recessive inheritance; RAG, recombination activating gene; DCLRE1C, DNA crosslink repair 1C; DNA-PKcs, DNA protein kinase catalytic subunit; JAK3, Janus activating kinase 3; IL7Rα, IL-7 receptor α-chain; EBV, Epstein–Barr virus.

The genetic basis of SCID

of SCID do not fit into this classification and, therefore, we will use the alternative approach involving cellular function for characterization of these forms (Table 2).

**T-B-NK- SCID**

The two identified T-B-NK- SCID forms are adenosine deaminase deficiency and reticular dysgenesis (RD). Impaired survival of lymphocyte precursors is observed in both forms.

**ADA deficiency**

With an incidence of 1 in 200,000 live births, ADA deficiency accounts for approximately one-third of all cases of AR SCID and approximately 15% of all cases of SCID. ADA deficiency is caused by mutations in the ADA gene at 20q13.11. ADA is an enzyme of the purine salvage pathway that mediates conversion of adenosine (and deoxyadenosine) to inosine (and deoxyinosine). In the absence of functional ADA, there is an intracellular accumulation of the phosphorylated metabolites of adenosine and deoxyadenosine. These products are toxic to lymphoid precursors in the bone marrow and thymus. Approximately 90% of ADA-deficient individuals have a classic severe SCID phenotype and they develop severe infections in the first months of life. Most of the remainder has a “delayed” or “late onset” form that presents in late infancy or early childhood. The wide spectrum of the ADA-deficiency phenotype is largely related to the variability in genetic mutations. Clinical manifestations of ADA deficiency extend beyond the immune system (deafness, behavioral problems, cognitive deficits, gait abnormalities, costochondral abnormalities, and liver toxicity), reflecting the fact that ADA is a housekeeping enzyme.7,8

The definitive treatment of choice is hematopoietic stem cell (HSC) transplantation from an HLA identical sibling or other appropriate donor such as one who is unrelated. Enzyme replacement therapy with polyethylene glycol–ADA (PEG–ADA) is an effective, alternative therapeutic approach in some patients without an appropriate donor. There is a lack of data regarding the effect of PEG–ADA treatment on neurologic abnormalities.9 ADA SCID was the first human disease treated by gene therapy.

**Reticular dysgenesis**

This form is one of the rarest and most severe types of SCID. Severe infections occur earlier than in other forms of SCID due to profound neutropenia, in addition to markedly decreased T and NK cells. B cells are absent to low normal. In addition, patients with RD also have sensorineural deafness.10
Table 2 Classification of SCID variants based on normal T-cell development

<table>
<thead>
<tr>
<th>Gene/locus MIM number</th>
<th>Specific manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microcephaly, developmental delay, facial dysmorphism, radiation sensitivity. May present with Omenn syndrome or with a delayed clinical onset</td>
<td></td>
</tr>
<tr>
<td>Necrotizing granulomatous skin lesions</td>
<td></td>
</tr>
<tr>
<td>Lymphocytic infiltration of tissues (lung, liver, gut, and bone), autoimmunity (may resemble IPEX syndrome)</td>
<td></td>
</tr>
</tbody>
</table>

This AR SCID is caused by mutations in the mitochondrial adenylate kinase (AK)2 gene. This enzyme regulates levels of adenosine diphosphate. AK2 deficiency results in increased apoptosis of myeloid and lymphoid precursors.

**T−B−NK+ SCID**

All the known causes for T−B−NK+ SCID syndromes involve defects in V(D)J recombination. This form of AR SCID phenotype accounts for 20% to 30% of all cases of SCID. It includes defects in RAG1 and RAG2, Artemis (DCLRE1C), and the DNA protein kinase catalytic subunit (DNA-PKcs). There are two principal types of patients with T−B−NK+ SCID associated with V(D)J recombination defects – those with and without radiation sensitivity.

**RAG1/RAG2**

Mutations in these genes are not associated with radiation sensitivity since these genes are expressed exclusively in lymphocytes and mediate the creation of double-strand DNA breaks at the sites of recombination and in signal sequences during T- and B-cell receptor gene rearrangement. Nonhomologous end joining (NHEJ), which is a common machinery repair process found in many other tissues, is normal in individuals with RAG1 or RAG2 defects. Certain RAG mutations that result in partial protein expression and limited production of T and B cells are known to cause OS. Hypomorphic RAG mutations have also been associated with a novel phenotype characterized by granuloma formation, EBV-related lymphoma, and survival into late childhood.
According to our local experience, XL-SCID is rare in Israel, while the most common phenotype is T–B– SCID due to RAG1/RAG2 mutations. This phenomenon is probably due to the high rate of consanguinity among our Arab-origin population, which accounts for approximately 20% of the whole population, and for more than 50% of our SCID patients.\textsuperscript{16,17}

Artemis and DNA-PKcs lead to increased sensitivity to ionizing radiation, since these gene products are important in the process of NHEJ required for repair of double-strand DNA breaks caused by radiation.

**Artemis**

Artemis deficiency is also known as Athabascan SCID (SCIDA), since a founder mutation in *Artemis* is found with increased frequency in Native Americans speaking one of the Athabascan family languages (eg, Apache, Navajo).\textsuperscript{18} In addition to T-cell maturation arrest, mutations in the *Artemis* gene result in B-cell differentiation arrest at the pre-B-cell-receptor checkpoint.\textsuperscript{19}

**DNA-PKcs**

*DNA-PKcs* regulates *Artemis* by both phosphorylation and complex formation to permit enzymatic activities that are critical for V(D)J recombination and for NHEJ.

Intriguingly, the described functional missense *DNA-PKcs* mutation does not affect either *DNA-PKcs* kinase activity or autophosphorylation—a important event that remodels the protein. Yet the clinical and cellular phenotype is similar to that caused by *Artemis* deficiency, suggesting that the mutation precludes *Artemis* activation, an event known to be *DNA-PKcs* dependent.\textsuperscript{20}

**T–B+NK– SCID**

Gene mutations affecting the integrity of the common gamma chain (γc)/JAK3 signaling pathway result in the most common form of inherited T–B+NK– SCID. Despite the presence of normal numbers of B cells, cell activation, proliferation, and differentiation are impaired, resulting in profound hypogammaglobulinemia.

**X-linked SCID**

This form of SCID is due to defects in γc. Mutations in this gene lead to profound derangement of the immune system via the blockade of multiple cytokine pathways (IL-2Rγc is shared by the receptors of IL-4, IL-7, IL-9, IL-15, and IL-21), which are important for lymphocyte development and function.\textsuperscript{21,22} In particular, IL-7 mediates expansion of early thymocyte progenitors, whereas IL-15 plays a role in NK cell development. Accordingly, patients with XL-SCID lack both T and NK cells, whereas they have a normal number of circulating B lymphocytes.\textsuperscript{23}

XL-SCID patients usually have the classic clinical SCID phenotype. However, some patients have an atypical presentation such as an OS phenotype\textsuperscript{24} or a polymorphous lymphoproliferative disorder with Hodgkin-like features.\textsuperscript{25} The γc subunit is also involved in growth hormone-receptor signaling. Thus, growth failure seen in children with XL-SCID may also be due to the underlying genetic defect.\textsuperscript{26} The γ chain mediates signal transduction via its physical association with a member of the Janus family of protein kinases, JAK3.\textsuperscript{27} The primary therapy currently available for XL-SCID is hematopoietic cell transplantation. Of note is that, in some cases, gene therapy has been successful.

**JAK3 deficiency**

JAK3 (encoded on chromosome 19p12-13.1) mediates cytokine signal transduction and is essential for lymphoid cell development. SCID due to JAK3 deficiency is rare, accounting only for approximately 6% of all cases of SCID. This AR form of T–B+NK– SCID is identical to XL-SCID in cellular and clinical phenotypes. Rarely, partial JAK3 defects associated with low amounts of functional protein can present with mild immunodeficiency.\textsuperscript{27}

**T–B+NK+ SCID**

This SCID phenotype includes defects in the IL-7 receptor alpha chain (*IL-7Rα*; also called CD127), actin-regulating protein, coronin 1A (*CORO1A*), CD45 (also called protein-tyrosine phosphatase receptor-type C; *PTPRC*), and the CD3 chains: CD3 delta (*CD3D*), CD3 epsilon (*CD3E*), and CD3 zeta (*CD3Z*).

**IL-7Rα chain deficiency**

This defect is the third most common type of SCID. *IL-7Rα* (encoded on chromosome 5p13) plays a critical role in cytokine signaling that is necessary for T-cell development. Although both T-cell and B-cell progenitors express the functional IL-7 receptor that consists of *IL-7Rα* and a γc chain, this lymphocyte-receptor system is critical for the T lineage, but not for the B lineage, or for NK-cell development. IL-15 promotes NK-cell differentiation and maturation. Many patients have been identified with a classic SCID phenotype and they lack the *IL-7Rα* chain.\textsuperscript{28,29} Mutations in the *IL-7Rα* gene can also present with an OS phenotype.\textsuperscript{30}
Actin-regulating protein coronin IA deficiency

Coronin 1A (encoded on chromosome 16p11.2) is involved in actin cytoskeleton regulation and is essential for T-cell immigration from the thymus to the secondary lymphoid organs. Defects in Coronin 1A lead to an absence of normal peripheral T cells and to a classic SCID phenotype. The thymus is present, unlike in most other forms of SCID.31

CD45 deficiency

CD45, the leukocyte common antigen (encoded on chromosome 1q31-q32) is a transmembrane tyrosine phosphatase involved in TCR signaling and T-cell development in the thymus. Only a few patients have been identified with classic SCID due to CD45 deficiency.32

CD3 complex component deficiencies

The CD3 complex plays a major role in signaling through the TCR, which is essential for the normal maturation of T cells. Mutations in the genes encoding CD3 chains (CD3 delta, CD3 epsilon, and CD3 zeta) appear to have an AR pattern of inheritance and have been reported in several patients. The clinical features are highly variable, depending upon the affected chain and mutation. Hypomorphic mutations in genes that are typically associated with SCID can allow residual T-cell development. In these cases, impaired cross-talk between thymocytes and thymic epithelial cells might compromise mechanisms of central tolerance, with failure to delete autoreactive T cells, and with impaired generation of regulatory T (Treg) cells. Accordingly, autoimmune manifestations are common, with infiltration of target tissues by activated and oligoclonal T lymphocytes.33-35

Ommenn syndrome

OS is characterized by early postnatal diffuse exfoliative erythroderma, protracted diarrhea, lymphadenopathy, and hepatosplenomegaly, together with the typical recurrent severe infections. Laboratory investigations reveal prominent eosinophilia and lymphocytosis, mainly of T cells. These lymphocytes exhibit activation markers despite their highly restricted repertoire. Variable hypogammaglobulinemia with elevated levels of immunoglobulin E (IgE) and skewing toward TH2, the absence of B cells with minimal antibody response, and the absence of normal mitogenic responses are some of the common immune abnormalities in this syndrome. This peculiar phenotype was found to be associated with several different gene mutations including RAG1/2 and Artemis, IL-7Ra, RNA-processing endoribonuclease, DNA ligase IV, ADA, and γc.15,36

T+B+NK+ SCID

Other forms of combined immunodeficiency have many of the elements of the clinical presentation of SCID, including opportunistic infections. These forms of combined immunodeficiency are usually distinguished by distinctive laboratory features and other elements of the clinical presentation. However, in some cases, the distinction between SCID and combined immunodeficiency (CID) is only made by molecular testing.

In this chapter, we took the approach of dissecting the different types of SCID based on the normal process of development, activation, and maturation of T cells as described previously (Figure 1). Defects in T-cell development that occur beyond the CD4+ CD8+ double-positive cell stage result in SCID with residual numbers of T lymphocytes. These SCID variants include: DNA ligase IV; Cernunnos-XLF; CD3γ deficiency; MHC class I deficiency; CD8 deficiency; MHC class II deficiency; IL-2 receptor alpha chain (CD25) deficiency; p56lck deficiency; ZAP-70 deficiency; ORA1/CRACM1 and STIM1 deficiencies; signal transducer and activator of transcription 5b (STAT5b) deficiency; winged-helix nude (FOXN1) deficiency; PNP; CD40 and CD40 ligand deficiencies; Itk; and dedicator of cytokinesis 8 (DOCK8) deficiency.

DNA ligase IV (LIG4)

The DNA ends must be ligated as part of the DNA repair process and this is implemented by an LIG4-XRCC4 complex. XRCC4 (X-ray-complementing Chinese hamster gene 4) has no known enzymatic activity, but functions as a scaffolding protein that helps attract other repair proteins to the DNA break. XRCC4 stabilizes LIG4 and enhances its activity.

Patients with LIG4 syndrome present with microcephaly, developmental delay, facial dysmorphism, increased susceptibility to tumors, and a variable degree of immunodeficiency that ranges from SCID/OS, to hypogammaglobulinemia with impaired class-switch recombination, to moderate, or even very modest defects in T- and B-cell immunity.37-39

Cernunnos–XLF

Defects in the NHEJ factor 1 gene (NHEJ1 gene) that codes for the protein Cernunnos, also known as the XRCC4-like factor (XLF), lead to a T–B–NK+ radiation-sensitive SCID phenotype with associated developmental delay and microcephaly. T cells are absent, except for memory
Figure 1 Genes with mutations that cause monogenic, severe T-cell immunodeficiency in humans can be intrinsic to the thymic epithelium or to T cells. (A) Genetic defects that are intrinsic to thymic epithelial cells ultimately affect the antigen-presentation pathway. (B) Genetic defects that are intrinsic to T cells include those that affect T-cell receptor (TCR) signaling, cytokine signaling, somatic recombination, or basic cellular processes. Other genes that are important to these pathways or processes, but have not been linked to severe T-cell deficiency in humans are shown in grey. Copyright © 2008. Nature Publishing Group. Adapted with permission from Liston A, Enders A, Siggs OM. Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat Rev Immunol. 2008;8:546.

Abbreviations: ADA, adenosine deaminase; ATM, ataxia-telangiectasia mutated; CBL, Casitas B-lineage lymphoma; CIITA, class II transactivator; DCLRE1C, DNA crosslink repair 1C; DNMT3β, DNA cytosine-5 methyltransferase 3β; ER, endoplasmic reticulum; FOXN1, forkhead box N1; GADS, GRB2-related adaptor protein; IL-2Rγ, IL-2 receptor γ-chain; IL-7, interleukin-7; IL-7Rα, IL-7 receptor α-chain; JAK, Janus kinase; LAT, linker for activation of T cells; LIG4, ligase IV; MRE11A, meiotic recombination 11 homolog A; Nibrin, Nijmegen breakage syndrome 1; NP, nucleoside phosphorylase; CRACM1, calcium release-activated calcium modulator 1; RAG, recombination-activating gene; RFX5, regulatory factor X5; RFXANK, RFX-associated ankyrin-containing protein; RFXAP, RFX-associated protein; RMRP, RNA component of mitochondrial RNA-processing endoribonuclease; SLP76, SRC-homology-2-domain-containing leukocyte protein of 76 kDa; SMARCAL1, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a-like 1; TAP, transporter associated with antigen processing; TAPBP, TAP-binding protein; TSAD, T-cell-specific adaptor protein; ZAP70, ζ-chain-associated protein kinase of 70 kDa.

T cells, and patients have a progressive loss of B cells. XLF-Cernunnos is a core protein of the NHEJ pathway of DNA double-strand break repair. The roles of the Cernunnos-XLF protein are still being elucidated. Crystallography suggests that it is part of the XRCC4-LIG4 complex. It enhances the DNA ligation activity of the XRCC4-LIG4 complex by promoting its re-adenylation and appears to play an essential role in gap filling by either polymerase during NHEJ, suggesting that it plays a major role in aligning the two DNA ends in the repair complex.40,41

**CD3γ deficiency**

CD3γ deficiency is an AR immunodeficiency caused by mutations in the gene coding for T-cell surface glycoprotein
CD3γ chain precursors. Affected patients have decreased T-cell numbers and function. B cells are variably affected. Patients with CD3γ deficiency have varying phenotypes, with some having SCID-like symptoms and some having a benign course.42

MHC class I deficiency (Bare lymphocyte syndrome type I)
Most patients with MHC I expression abnormalities exhibit decreased or absent MHC I expression on the cell surface, low numbers of CD8+ T cells, and decreased NK cell-killing activity. However, they have normal antibody-dependent cell-mediated cytotoxicity.43 The clinical presentation is highly variable, depending upon the amount of MHC class I expression. Affected patients with a severe reduction in MHC class I expression also tend to have necrotizing granulomatous skin lesions.44 Some patients with MHC class I deficiency have defects in the transporter associated with antigen processing: (TAP) 1, TAP2, or tapasin. TAP1 and TAP2 are required for peptide transport from the cytosol into the ER lumen, where the assembly of the MHC class I complex takes place. Tapasin serves as a docking site that is specific for interaction with class I MHC molecules, which is essential for peptide loading and expression. The exact defect has not been identified in other patients with MHC class I deficiency. The inheritance pattern is unclear due to its rarity.45

CD8 deficiency
CD8 is a TCR accessory molecule that binds to class I MHC. CD8 is primarily expressed on cytotoxic T cells, but is also found on NK cells. A single patient has been described with symptomatic CD8 deficiency due to a homozygous mutation in the gene encoding the CD8 alpha chain (CD8α) on chromosome 2p12. He had recurrent sinopulmonary infections, which suggested a humoral deficiency. However, his immunoglobulin levels and specific antibody titers were normal. CD4+ T-cell, B-cell, and NK-cell percentages and absolute counts were normal, but CD8+ T cells were completely absent. Two younger sisters, who also had absent CD8+ T cells, were asymptomatic at the time of the report, reflecting the importance of other factors (such as epigenetics and infections) in these complex diseases.46

MHC class II deficiency (Bare lymphocyte syndrome type II)
This is an AR disease. Both constitutive and induced MHC class II expressions are compromised. The exact molecular defects have not been identified in most patients, but are suspected to involve mutations in MHCII promoter complex DNA-binding regulatory factors (CIITA-class II transactivator, RFX5, RFXAP, and RFXANK). The majority of identified defects are RFXANK mutations (chromosome 19p12). The disease is more common in certain geographic regions (North Africa47 and Palestinians [Broides A, email communication, 2011]). Patients with MHC II expression abnormalities exhibit complete absence of MHC II expression on B cells, a normal number of B cells in peripheral blood, hypogammaglobulinemia, and poor specific-antibody responses. In addition, CD4 lymphopenia, with a proportional increase in CD8, a normal number of T cells in peripheral blood, but with decreased in vitro T-cell response to antigens are observed. Class II MHC deficiency generally results in a clinical picture of severe combined immune deficiency. However, milder cases have been described.48

Interleukin-2 receptor alpha chain (CD25) deficiency
CD25 deficiency is extremely rare. Only a few patients have been described with lesions in the IL2-RA gene encoding the α-chain of the IL-2 receptor. This immunodeficiency is characterized by normal to modestly decreased numbers of circulating T cells, displaying abnormal proliferation, but normal B-cell development. Extensive lymphocytic infiltration of tissues including the lung, liver, gut, and bone, is observed, accompanied by tissue atrophy, and inflammation.49 A phenotype resembling the syndromes of immune dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) – a syndrome that is more often associated with mutations of the transcription factor FOXP3 – has also been described.50

Lymphocyte-specific protein tyrosine kinase (Lck or p56lck) deficiency
Initial transduction of antigen-binding signals from the TCR/CD3 complex is primarily dependent upon two protein tyrosine kinases: Lck and ZAP-70. Several patients have been reported with a deficiency of Lck, which was activated upon engagement of the TCR-CD3 complex. Lck is a 56-kDa member of the Src-family tyrosine kinase family. Deficiency of Lck is reported to result in an immunodeficiency characterized by selective CD4 lymphopenia, decreased CD28 expression on CD8 cells, and low, to absent immunoglobulins. Patients demonstrate the typical failure to thrive that is seen in SCID.51
ZAP-70 deficiency

ZAP-70 deficiency is a rare combined immunodeficiency with an AR pattern of inheritance. Zeta chain-associated 70-kDa protein kinase (ZAP-70) is a signaling molecule associated with the TCR complex, which is expressed primarily in T cells. Most mutations occur within the kinase domain of the ZAP-70 protein, and significantly affect both protein stability, and catalytic activity. Deficiency of ZAP-70 (which was originally described in a Mennonite family) is characterized by the selective absence of circulating CD8+ T cells and by abundant CD4+ T cells in the peripheral blood that are unresponsive to TCR-mediated stimuli in vitro. All patients with ZAP-70 deficiency have normal to elevated numbers of circulating lymphocytes.

ORAI1/CRACM1 and STIM1 deficiencies

Lymphocyte activation after antigen stimulation is dependent upon store-operated entry of Ca²⁺ across the plasma membrane via Ca²⁺ release-activated Ca²⁺ (CRAC) channels. ORAI1 or calcium release-activated calcium modulator 1 (CRACM1) is the pore-forming subunit of the CRAC channel. Stromal interaction molecule 1 (STIM1) senses release of Ca²⁺ from endoplasmic reticulum stores and activates CRAC channels in the plasma membrane. Sustained Ca²⁺ influx induces expression of IL-2 and other cytokines. The clinical phenotypes of the ORAI1 defect and of the STIM defect are similar. Mutations in ORAI1 on chromosome 12q24 and STIM1 on chromosome 11q15.5 appear to have AR inheritance. The laboratory findings are similar for both of these defects. Lymphocyte counts are normal to slightly reduced, and immunoglobulin levels are normal to elevated. However, the T-cell proliferative response to mitogens and antigens is compromised and specific antibody response to vaccination is impaired. Non-progressive muscular hypotonia and abnormalities in dental enamel are seen in both ORAI1 and STIM1 deficiencies. Extensive ectodermal defects (ectodermal dysplasia and anhydrosis) are more prominent in patients with ORAI1 deficiency. Unique features of STIM1 deficiency are severe autoimmunity and partial iris hypoplasia.

Signal transducer and activator of transcription 5b (STAT5b) deficiency

Several patients have been identified with mutations in the STAT5b gene that cause a defect in the signaling pathways of receptors for IL-2, IL-4, macrophage colony-stimulating factor, and growth hormone. CD4+ CD25+ regulatory T cells are decreased in number in patients with STAT5b deficiency. Other immunologic parameters are variable, including T-, B-, and NK-cell levels, and T-cell proliferation. Patients present with signs of growth-hormone insensitivity, including short stature, a prominent forehead and saddle nose, and a high-pitched voice. Associated manifestations include eczema and autoimmunity as well.

Winged-helix nude (FOXN1) deficiency

This extremely rare disorder is caused by a homozygous defect in the forkhead box N1 (FOXN1) gene, which is the gene mutated in “nude” SCID mice. FOXN1 is a member of the winged-helix domain family of transcription factors. This protein is involved in the development of the thymus as well as formation of hair and nails. It also may be involved in brain and neural tube development. Patients with defects in this gene have decreased circulating T cells, mainly due to low levels of CD4+ T cells. T-cell proliferative responses to mitogens were abnormal. Congenital alopecia and nail dystrophy are characteristic features. Additional defects, including spina bifida and anencephaly, have been described in a fetus.

Purine nucleoside phosphorylase (PNP) deficiency

PNP follows ADA in the purine salvage pathway, and PNP deficiency causes SCID because excess deoxyguanosine and deoxyguanosine triphosphate lead to increased apoptosis of lymphocytes, mainly immature T lymphocytes. PNP-deficient cells do not produce uric acid and, therefore, low uric acid in serum (<2 mg/dL) supports the diagnosis. PEG-PNP is not commercialized and gene therapy is still experimental in mice. HSCT is the only available therapy, but it does not correct the severe neurological manifestations usually present (hypertonia, hypotonia, ataxia, psychomotor delay). Autoimmunity (hemolytic anemia, autoimmune thrombocytopenia, neutropenia, arthritis, etc) and neoplasia are also frequent.

CD40 and CD40 ligand deficiencies

CD40 is a molecule on the surface of B cells and mononuclear cells (including dendritic cells) that interacts with its CD40 ligand (CD40L) on the surface of activated CD4+ T cells. Defects in CD40L or CD40 cause defective isotype switching and impaired dendritic cell signaling. Mutations in CD40L...
(CD154) are responsible for most cases of hyper-IgM (HIGM) syndrome. The principal laboratory findings of HIGM syndrome are low serum levels of IgG and IgA, in combination with normal or elevated concentrations of IgM. Circulating B cells are normal in number, but exclusively express cell-surface IgM and IgD. Vaccination may elicit specific IgM responses. No other isotypes are produced and there is no B-cell memory. CD40L is located on the X chromosome, while the gene encoding CD40 (TNF-receptor superfamily member 5 or TNFRSF5) is located on chromosome 20q12-q13.2. Mutations in this gene underlie a clinically indistinguishable disorder with AR inheritance. Patients with HIGM usually present within the first two years of life with the combination of recurrent respiratory tract infections with encapsulated bacteria and opportunistic infections. Lymphadenopathy and hepatosplenomegaly are often present. They are also prone to neutropenia, thrombocytopenia, anemia, sclerosing cholangitis, cirrhosis, and lymphoproliferative disease. Increased rates of malignancy such as hepatocellular, bile duct, and neuroendocrine carcinomas are also reported.

**Interleukin-2 tyrosine kinase (Itk) deficiency**

Itk deficiency is characterized by lymphoproliferation and severe immune dysregulation following EBV infection and is inherited as an AR disorder. Itk is a member of the TEC kinase family. These proteins are important mediators of antigen-receptor signaling in lymphocytes, and Itk is believed to be the predominant TEC kinase in T cells, and one of the key molecules involved in NKT cell maturation and survival. Itk deficiency was recently identified in female siblings who presented with EBV-associated lymphoproliferation, an absence of NKT cells, and hemophagocytic lymphohistiocytosis.

**Dedicator of cytokinesis 8 (DOCK8) deficiency**

Several patients have been identified with loss of functional homozygous or compound heterozygous mutations in an uncharacterized gene, DOCK8, which is expressed in lymphocytes. Most patients have low absolute lymphocyte counts, including low T cells; B and NK cells are also low in many patients. Most patients also have eosinophilia and elevated IgE. IgM levels are low, but many patients have increased IgG levels. IgG antibody responses to bacterial and viral antigens are variable. Common clinical features include recurrent respiratory tract infections, extensive cutaneous viral and bacterial infections, severe atopy, and susceptibility to cancer (vulvar, facial, and anal squamous-cell dysplasia and carcinomas, and T-cell lymphoma/leukemia).

**Other well-defined immunodeficiency syndromes**

In addition to the above-described syndromes, there are other well-defined primary immunodeficiency disease (PID) syndromes with a variable degree of immune dysfunction such as Wiskott–Aldrich syndrome, DNA repair defects (ataxia telangiectasia, Bloom and Nijmegen syndromes), and others. Some of them can present with the typical clinical and laboratory features of SCID/CID. Herein, we discuss some of these syndromes in detail.

**DiGeorge syndrome (DGS)**

DGS (OMIM 188400) results from dysmorphogenesis of the third and fourth pharyngeal pouches during early embryogenesis, leading to hypoplasia or aplasia of the thymus and parathyroid glands. Other structures forming at the same age are also frequently affected, resulting in anomalies of maxilla, mandible, aortic arch, cardiac outflow tract, and external/middle ear. The classical presentation of DGS is the triad of conotruncal cardiac anomalies, hypoplastic thymus, and hypocalcemia, although the phenotype is variable. Palatal abnormalities and developmental delay are common. Approximately 90% of patients with DGS have spontaneously arising heterozygous microdeletions in chromosome 22q11.2. Defects in the gene encoding the T-box transcription family member, TBX1, are responsible for the DGS phenotype. The basis for the syndrome without the characteristic deletion is often unknown. Some patients will have a known exposure to toxins such as isotretinoin or maternal alcohol ingestion. There is also a small subset that shows the deletion of chromosome 10p13-14.

The immunodeficiency has been characterized as either complete or partial, based on the level of immunologic function. The minority of patients (approximately 1%) have a complete absence of thymic tissue and profound immunodeficiency. Patients with complete DGS resemble patients with SCID. Atypical cases phenotypically appear to be similar to OS. Complete DGS is fatal if not recognized and treated with a thymic or HSC transplant.

**Cartilage-hair hypoplasia (CHH)**

CHH (OMIM 250250) is an AR, predominantly T-cell deficiency associated with metaphyseal chondrodysplasia, a form
of short-limb dwarfism. Associated features may include
fine sparse hair, cellular and humoral immunodeficiencies,
Hirschsprung disease, hematologic and skin malignancies,
autoimmune disease, and bronchiectasis. The responsible
gene for CHH has been mapped to 9p21-p12 and shown to
be the gene encoding the ribonuclease mitochondrial RNA-
processing (RMRP) protein.

Phenotypic heterogeneity is great and the immunode-
ficiency is variable. Cell-mediated immunodeficiency is
most commonly reported. SCID is known to occur in the
setting of CHH. SCID may present with severe T- and B-cell
functional defects, but with quantifiable cell counts, or with
an OS phenotype. Stem-cell transplantation has resulted in
immunologic reconstitution in some CHH patients with the
SCID phenotype.  

Hereditary folate malabsorption
(HFM)

HFM (OMIM 229050) is an extremely rare AR cause of
folic acid deficiency. It presents early in life with diarrhea,
failure to thrive, and megaloblastic anemia often accompa-
nied by leukopenia, and/or thrombocytopenia. HFM patients
can develop progressive neurologic deterioration (ataxia,
seizures, and mental retardation) unless they are treated
promptly and aggressively. Family studies have shown this
disorder to be due to mutations in a proton-coupled folate
transporter (PCFT), resulting in abnormal folate transport
across the gastrointestinal tract and the blood–brain barrier.
HFM can present with life-threatening infections due to
profound immunological defects that may mimic SCID. The
immune defects are fully reversible with adequate folate
repletion.  

Hoyeraal–Hreidarsson (HH)

HH syndrome (OMIM 300240) represents a severe variant
of dyskeratosis congenita (DC). This rare, progressive,
multisystemic disorder is characterized by intrauterine
growth retardation, microcephaly, cerebellar hypopla-
sia, mental retardation, early onset bone marrow failure,
progressive combined immune deficiency, and aplastic
anemia. DC and HH result from heterogeneous telomere
defects.  

Gene therapy

Gene therapy for SCID is still in its infancy. Virus-based
vectors are widely used in HSC gene therapy, and have the
ability to integrate permanently into genomic DNA, thus
driving long-term expression of corrective genes in all
hematopoietic lineages. To date, HSC gene therapy has been
successfully employed in the clinic for improving clinical
outcomes in small numbers of patients with ADA SCID and
XL-SCID.

ADA deficiency was the first genetic disorder to be treated
by gene therapy; however, the first cases failed to achieve
sustained T-cell and normal ADA levels.  
Since 2000, over
30 patients with ADA deficiency have been treated with
gene therapy throughout the world. Most cases have shown
successful outcomes, achieving immune reconstitution,
restoration of thymic activity, systemic detoxification, and
long-term engraftment.  

The possible role of gene therapy continues to evolve
and a second trial was carried out on XL-SCID patients. To
date, gene therapy results are available for 20 patients with
a typical XL-SCID. Most patients have shown substantial
improvements in clinical and immunological features. How-
ever, five of the 20 patients developed a T-cell acute
leukemia 2 to 5.5 years after gene therapy. In all cases, it
was found that the abnormal clone had one or two provirus
integrations within a proto-oncogene locus. Many other
genomic abnormalities were found. Accordingly, the clin-
cial trials were discontinued. Today, gene therapy is allowed
to continue on a case-by-case basis if no other treatment is
available.  

Numerous studies have been performed to understand the
molecular basis of vector-mediated genotoxicity, with the
aim of developing safer vectors and lower risk gene-therapy
protocols. One such approach involves self-inactivating
gammaretrovirus and lentivirus-based vectors, which, when
integrated, lack enhancer and promoter sequences from the
long terminal repeat.  
These new vectors should decrease or
alleviate the risks of proto-oncogene activation by insertional
mutagenesis.  

Meanwhile, vector-mediated genotoxicity has fostered a
growing interest for alternative strategies, referred to as
“targeted approaches,” that consist of replacing random inte-
gration of therapeutic transgenes by targeted insertion or even
correction of the deleterious mutation. Results are beginning
to accumulate for clinical trials using new viral vectors and
the first clinical trial using a targeted approach has been
initiated.  
Although additional time is needed to evaluate,
more precisely, the potentials and limits of each method,
targeted approaches remain today, at least conceptually, more
attractive than classical gene-transfer techniques.  

Disclosure

The authors report no conflicts of interest in this work.
References


